PRESS RELEASE | Euformatics paves its way further to the Middle East market with Genetrics
Espoo, October 6th, 2023. Euformatics has entered into a partnership with Genetrics to serve as their channel partner for the distribution of their
PRESS RELEASE | Euformatics, Viennalab Diagnostics and Oncompass Medicine, awarded a contract to develop an end-to-end liquid biopsy solution for eight leading European oncology centers
Espoo, Finland, September 26th, 2023. Euformatics, a global leader in NGS data quality control and variant interpretation, together with ViennaLab
PRESS RELEASE | Euformatics expands in Eastern Europe partnering with ELTA 90 and signs first joint customer in North Macedonia.
Espoo, September 2023. Euformatics, a Finnish bioinformatics company that develops world-leading NGS interpretation and quality control tools,
PRESS RELEASE | Euformatics, Oncompass Medicine and Institut Curie awarded Eurostars funding to develop an oncology solution with genomic noise canceling
Espoo, Finland, September 12th, 2023. Euformatics has partnered with Oncompass Medicine from Hungary and Institut Curie from France and submitted a
PRESS RELEASE | Euformatics partners with Cerba to provide software tools for clinical genomic data analysis
Espoo, Finland, September 6th, 2023. Euformatics, a world leader in NGS quality control and variant interpretation tools, announced that it has
PRESS RELEASE | Euformatics partners with Appolon Bioteck to expand in the French market
Espoo, September 6th, 2023. Euformatics, a Finnish bioinformatics company that develops world-leading genomic data analysis tools, announced that it
PRESS RELEASE | Euformatics expands in the Middle East in partnership with Zahrawi Medical Group for Bahrain, Oman and the UAE markets
Espoo, Finland, May 2023. Euformatics, a Finnish bioinformatics company that develops world-leading NGS interpretation and quality control tools,
